Evidence map›Paper›PMID 40995126›Full record

ArticleiScience2025

LncRNA

Lan Li, Xue-Ni An, Yong-Tong Ruan, Xin Liang, Jing-Lan Hao, Guang-Xun Gao, Jun-Fang Bi, Yan-Rong Gao, Xiao Lu, Hai-Long Tang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lan LiCollege of Life Sciences, Shaanxi Normal University, Xi'an 710119, China.
Xue-Ni AnCollege of Life Sciences, Shaanxi Normal University, Xi'an 710119, China.
Yong-Tong RuanCollege of Life Sciences, Shaanxi Normal University, Xi'an 710119, China.
Xin LiangCollege of Life Sciences, Shaanxi Normal University, Xi'an 710119, China.
Jing-Lan HaoCollege of Life Sciences, Shaanxi Normal University, Xi'an 710119, China.
Guang-Xun GaoDepartment of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Jun-Fang BiDepartment of Combined Traditional Chinese Medicine and West Medicine, Shijiazhuang Traditional Chinese Medicine Hospital, Shijiazhuang 050051, China.
Yan-Rong GaoShaanxi Rehabilitation Hospital, Xi'an 710065, China.
Xiao LuCollege of Life Sciences, Shaanxi Normal University, Xi'an 710119, China.
Hai-Long TangDepartment of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Ping GaoCollege of Life Sciences, Shaanxi Normal University, Xi'an 710119, China.
Xiao-Ming DongCollege of Life Sciences, Shaanxi Normal University, Xi'an 710119, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is an aggressive clonal malignancy of hematopoietic progenitors with poor clinical outcomes. Though many patients respond well to induction chemotherapy, relapse occurs. The mechanisms underlying AML chemoresistance remain unclear. In our study, we performed whole transcriptome sequencing (WTS) on diagnosed AML samples sensitive or resistant to IA (idarubicin and cytarabine) induction treatment. We observed that lncRNA

Indexed as

BiochemistryCancerPharmacology

Identifiers

PMID40995126
PMCPMC12454627

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.